Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05422781
Title Study To Evaluate The Safety, Tolerability And Immunogenicity Of 4 mg Of ITI-3000 In Patients With Polyomavirus-Positive Merkel Cell Carcinoma (MCC)
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Immunomic Therapeutics, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.